Pipeline / BPC-612

immunology · biologic

BPC-612 — Moderate to severe ulcerative colitis

A humanized antibody blocking TL1A for inflammatory bowel disease. The Phase 2 program is enrolling patients with moderate to severe ulcerative colitis.

phase 2 Target: Tumor necrosis factor-like ligand 1A (TL1A) Sample data

Investigational candidate. BPC-612 has not been approved by any regulatory authority.

Mechanism of action

How the molecule works.

BPC-612 neutralizes TL1A, a cytokine that sits at the intersection of mucosal inflammation and fibrosis, reducing both inflammatory signaling and tissue remodeling.

Milestones

Program timeline.

  1. 2022 Lead selected done
  2. 2023 Phase 1 first-patient-in done
  3. 2024 Phase 1 complete done
  4. 2025 Phase 2 enrolling current
  5. 2026 Phase 2 interim planned

Clinical trials

1 trial for BPC-612.

NCT-BPC612-201

Phase 2 induction study of BPC-612 in ulcerative colitis

Recruiting phase 2 95/180 enrolled

Publications

3 related publications.

  • Gastroenterology 2023

    Neutralization of TL1A reduces mucosal inflammation in preclinical colitis models

    Watanabe K, Okonkwo E, Lindgren S, et al.

    Mechanism of action and preclinical efficacy of BPC-612, a humanized anti-TL1A antibody for inflammatory bowel disease.

    DOI: 10.1053/j.gastro.[sample]
  • Cell Chemical Biology 2022

    A structure-guided platform for the discovery of selective kinase inhibitors

    Raman A, Fischer L, Becker T, et al.

    An overview of the structure-guided discovery platform underlying the BPC-101 and BPC-305 programs.

    DOI: 10.1016/j.chembiol.[sample]
  • PNAS 2022

    Antibody and antibody-drug conjugate discovery using engineered Fc libraries

    Hoffmann P, Shah N, Watanabe K, et al.

    Description of the Fc engineering library used to discover BPC-203 and to assemble the BPC-402 linker-payload.

    DOI: 10.1073/pnas.[sample]
Back to pipeline Contact about this program